Engineered immune cells take on relapsed blood cancers

NCT ID NCT07584889

Recruiting now Disease control Sponsor: Shenzhen University General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing a new type of CAR-T cell therapy, called CD19-CAR.p40-T, in 10 adults with B-cell lymphoma, acute lymphoblastic leukemia, or acute myeloid leukemia that has come back or not responded to treatment. Participants receive chemotherapy followed by an infusion of their own genetically modified immune cells designed to target and kill cancer cells. The study aims to first check safety, then see if the treatment shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CD19-CAR.p40-T cells (a type of genetically modified immune cell)
What this could lead to: If it works, this could offer a new treatment option for people with blood cancers that have not responded to standard therapies.
What could go wrong: This is a very early, small trial with only 10 participants, so results may not apply broadly. CAR-T therapy can cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia acute myeloid leukemia B-cell neoplasm Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA ACUTE MYELOID LEUKEMIA B CELL LYMPHOMA

Contacts and locations

Locations

Shenzhen University General Hospital
RECRUITING

Shenzhen, Other (Non U.s.), 518055, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.